Hallucinogens and Related Drugs

  • Marc A. Schuckit
Part of the Critical Issues in Psychiatry book series (CIPS)


Both marijuana and the hallucinogens produce a change in the level of consciousness, and both are capable of inducing hallucinations. However, in the usual doses taken, the predominant effect of cannabis is to alter the “feeling state” with less intensity and without frank hallucinations. The drugs discussed in this chapter produce more intense changes and often yield abnormal sensory inputs of a predominantly visual nature (illusions or hallucinations), even at low doses.


Anorexia Nervosa Visual Hallucination Toxic Reaction Related Drug Lysergic Acid Diethylamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jaffe, J. H. Drug addiction and drug abuse. In A. G. Gilman, L. S. Goodman, T. W. Rall, und F. Murad (Eds.), The Pharmacological Basis of Therapeutics ( 7th ed. ). New York, Macmillan, 1985, pp. 532–581.Google Scholar
  2. 2.
    Leonard, H. L., und Rapoport, J. L. Treatment of anorexia nervosa patient with fluoxetine. American Journal of Psychiatry 144: 1239–1240, 1987.PubMedGoogle Scholar
  3. 3.
    Hollister, L. E. Clinical aspects of use of phenylalkylamine and indolealkylamine hallucinogens. Psychopharmacology 22: 977–979, 1986.Google Scholar
  4. 4.
    Dorrance, D. L., Janiger, O., und Teplitz, R. L. Effect of peyote on human chromosomes: Cytogenetic study of the Huichol Indians of Northern Mexico. Journal of the American Medical Association 234: 299–302, 1975.PubMedCrossRefGoogle Scholar
  5. 5.
    Dobkin de Rios, M. Man, culture and hallucinogens: An overview. In V. Rubin (Ed.), Cannabis and Culture. The Hague: Mouton, 1975, pp. 76–92.Google Scholar
  6. 6.
    Hofmann, F. G., und Hofmann, A. D. A Handbook on Drug and Alcohol Abuse. New York: Oxford University Press, 1975.Google Scholar
  7. 7.
    White, F. J., und Appel, J. B. Lysergic acid diethylamide (LSD) and lisuride: Differentiation of their neuropharmacological actions. Science 216: 535–537, 1982.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobs, B. L., und Trulson, M. E. Mechanisms of action of LSD. American Scientist 67: 396–404, 1979.PubMedGoogle Scholar
  9. 9.
    Weaver, K. E. C. LSD and schizophrenia. Archives of General Psychiatry 41:631, 1984.Google Scholar
  10. 10.
    Jacobs, B. L. Effects of classical hallucinogenic drugs are mediated by an action at postsynaptic serotonergic sites. Paper presented at the American College of Neuropsychopharmacology Annual Meeting, Maui, Hawaii, December 10, 1985.Google Scholar
  11. 11.
    Vardy, M. M., und Kay, S. R. LSD psychosis or LSD-induced schizophrenia? Archives of General Psychiatry 40: 877–883, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Segal, D. S., und Schuckit, M. A. Animal models of stimulant-induced psychosis. In I. Creese (Ed.), Stimulants: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven Press, 1982, pp. 131–168.Google Scholar
  13. 13.
    Cohen, S. The hallucinogens. Drug Abuse and Alcoholism Newsletter 13, July 1984.Google Scholar
  14. 14.
    Diagnosis and management of reactions to drug abuse. Medical Letter 19:13–16,1977.Google Scholar
  15. 15.
    Ungerleider, J. T., und Frank, I. M. Emergency treatment of adverse reactions to hallucinogenic drugs. In P. G. Bourne (Ed.). A Treatment Manual for Acute Drug Abuse Emergencies. Washington, D.C.: U.S. Govemment Printing Office, 1974, pp. 73–76.Google Scholar
  16. 16.
    Davis, M., Kehne, J. H., Commissaris, R. L., und Geyer, M. A. Effects of hallucinogens on unconditioned behaviors in animals. In B. L. Jacobs (Ed.), Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives. New York, Raven Press, 1984, pp. 35–75.Google Scholar
  17. 17.
    Schlemmer, R. F., Nawara, C., Heinze, W. J., et al Influence of environmental context on tolerance to LSD-induced behavior in primates. Biological Psychiatry 21: 314–317, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Cohen, S. (Ed.). Pharmacology of drugs of abuse. Drug Abuse and Alcoholism Newsletter 5: 1–4, 1976.Google Scholar
  19. 19.
    Brown, J. K., und Malone, M. H. Some U.S. street drug identification programs. Journal of the American Pharmaceutical Association 13: 670–675, 1973.PubMedGoogle Scholar
  20. 20.
    Bowers, M. B., Jr. Psychoses precipitated by psychotomimetic drugs: A follow-up study. Archives of General Psychiatry 34: 832–835, 1977.PubMedCrossRefGoogle Scholar
  21. 21.
    Editorial: Epidemiology of drug usage. Lancet 1: 147–148, 1985.Google Scholar
  22. 22.
    Smart, R. G., Adlaf, E. M., und Goodstadt, M. S. Alcohol and other drug use among Ontario students: An update. Canadian Journal of Public Health 77: 57–58, 1986.Google Scholar
  23. 23.
    Editorial: National survey finds continuing decline in use of illicit drugs by high school seniors. Hospital and Community Psychiatry 36: 1011, 1985.Google Scholar
  24. 24.
    Blackford, L. Student Drug Surveys-San Mateo County, California, 1968–1975. San Mateo, California: San Mateo County Department of Public Health and Welfare, 1975.Google Scholar
  25. 25.
    Shapira, J., und Cherubin, C. E. Drug Abuse: A Guide for the Clinician. New York: American Elsevier, 1975.Google Scholar
  26. 26.
    Taylor, R. L., Maurer, J. I., und Tinklenberg, J. R. Management of “bad trips” in an evolving drug scene. Journal of the American Medical Association 213: 422–425, 1970.PubMedCrossRefGoogle Scholar
  27. 27.
    Frosch, W. A., Robbins, E. S., und Stern, M. Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization. New England Journal of Medicine 273:1235–1239, 1965.Google Scholar
  28. 28.
    Levy, R. M. Diazepam for LSD intoxication. Lancet 1: 1297, 1971.PubMedCrossRefGoogle Scholar
  29. 29.
    Goodwin, D. W., und Guze, S. B. Psychiatric Diagnosis ( 4th ed. ). New York: Oxford University Press, 1988.Google Scholar
  30. 30.
    Cohen, S. (Ed.). Flashbacks. Drug Abuse and Alcoholism Newsletter 6: 1–3, 1977.Google Scholar
  31. 31.
    Yager, J., Crumpton, E., und Rubenstein, R. Flashbacks among soldiers discharged as unfit who abused more than one drug. American Journal of Psychiatry 140: 857–861, 1983.PubMedGoogle Scholar
  32. 32.
    Forrest, J. A. H., und Tarala, R. A. 60 hospital admissions due to reactions to lysergide (LSD). Lancet 2: 1310–1313, 1973.PubMedCrossRefGoogle Scholar
  33. 33.
    Winek, C. L., Collom, W. D., und Bricker, J. D. A death due to 4-bromo-2,5-dimethoxyamphetamine. Clinical Toxicology 18: 261–266, 1981.PubMedCrossRefGoogle Scholar
  34. 34.
    Shoichet, R. Emergency treatment of acute adverse reactions to hallucinogenic drugs. In P. G. Bourne (Ed.). A Treatment Manual for Acute Drug Abuse Emergencies. Washington, D.C.: U.S. Government Printing Office, 1974, pp. 80–82.Google Scholar
  35. 35.
    Abruzzi, W. Drug-induced psychosis. International Journal of the Addictions 12:183–193, 1977.Google Scholar
  36. 36.
    Friedman, S. A., und Hirsh, S. E. Extreme hyperthermia after LSD ingestion. Journal of the American Medical Association 217:1549–1550, 1971.Google Scholar
  37. 37.
    Lake, C. R., Stirba, A. L., Kinneman, R. E. et al. Mania associated with LSD ingestion. American Journal of Psychiatry 138: 1508–1509, 1981.PubMedGoogle Scholar
  38. 38.
    Liskow, B. LSD and prolonged psychotic reactions. American Journal of Psychiatry 128:1154, 1972.Google Scholar
  39. 39.
    Glass, G. S., und Bowers, M. B. Chronic psychosis associated with long-term psychotomimetic drug abuse. Archives of General Psychiatry 23: 97–102, 1970.PubMedCrossRefGoogle Scholar
  40. 40.
    Ungerleider, J. T. LSD and the courts. American Journal of Psychiatry 126 (8):1179,1970.Google Scholar
  41. 41.
    Goldstein, J. A. Niacin and acute psychedelic psychosis. Biological Psychiatry 19: 272–273, 1984.PubMedGoogle Scholar
  42. 42.
    Grant, I., Mohns, L., Miller, M., und Reitan, R. M. A neuropsychological study of polydrug users. Archives of General Psychiatry 33: 973–978, 1976.PubMedCrossRefGoogle Scholar
  43. 43.
    Abraham, H. D. A chronic impairment of colour vision in users of LSD. British Journal of Psychiatry 140: 518–520, 1982.PubMedCrossRefGoogle Scholar
  44. 44.
    Culver, C. M., und King, F. W. Neuropsychological assessment of undergraduate marihuana and LSD users. Archives of General Psychiatry 31: 707–711, 1974.PubMedCrossRefGoogle Scholar
  45. 45.
    Smith, C. G., und Asch, R. H. Drug abuse and reproduction. Fertility and Sterility 48: 355–373, 1987.PubMedGoogle Scholar
  46. 46.
    Emanuel, I., und Ansell, J. S. LSD, intrauterine amputations, and amniotic-band syndrome. Lancet 2: 158–159, 1971.Google Scholar
  47. 47.
    Bloom, A. D. Peyote (mescaline) and human chromosomes. Journal of the American Medical Association 234: 313, 1975.PubMedCrossRefGoogle Scholar
  48. 48.
    Ricuarte, G., Bryan, G., und Strauss, L. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986–988, 1985.CrossRefGoogle Scholar
  49. 49.
    Bowen, J. S., Davis, G. B., Kearney, T. E., und Bardin, J. Diffuse vascular spasm associated with 4bromo-2,5-dimethoxyamphetamine ingestion. Journal of the American Medical Association 249:1477–1479, 1983.Google Scholar
  50. 50.
    Dietz, W. H., Jr., und Stuart, M. J. Nutmeg and prostaglandins. New England Journal of Medicine 294: 503, 1976.PubMedGoogle Scholar
  51. 51.
    Schulze, R. G. Nutmeg as a hallucinogen. New England Journal of Medicine 295: 174, 1976.PubMedGoogle Scholar
  52. 52.
    Faguet, R. A., und Rowland, K. F. “Spice cabinet” intoxication. American Journal of Psychiatry 135: 860–861, 1973.Google Scholar
  53. 53.
    Fink, P. J., Goldman, M. J., und Lyons, I. Morning glory seed psychosis. Archives of General Psychiatry 15: 209–213, 1966.CrossRefGoogle Scholar
  54. 54.
    Domino, E. F. The hallucinogens. In R. W. Richter (Ed.). Medical Aspects of Drug Abuse. New York: Harper und Row, 1975, pp. 210–217.Google Scholar
  55. 55.
    Molyneux, R. J. Loco intoxication: Indolizidine alkaloids of spotted locoweed (Astragalus lentiginosus). Science 216: 190–191, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Lane, G. A. Nitrous oxide is fetotoxic. Science 210: 889–890, 1980.CrossRefGoogle Scholar
  57. 57.
    Block, S. H. The grocery store high. American Journal of Psychiatry 135: 126, 1978.PubMedGoogle Scholar
  58. 58.
    Gillman, M. A. Safety of nitrous oxide. Lancet 2: 1397, 1982.PubMedCrossRefGoogle Scholar
  59. 59.
    Goode, E., und Troiden, R. R. Amyl nitrite use among homosexual men. American Journal of Psychiatry 136: 1067–1069, 1979.PubMedGoogle Scholar
  60. 60.
    McManus, T. F. Amyl nitrite. Lancet 1: 503, 1982.PubMedCrossRefGoogle Scholar
  61. 61.
    Lange, W. R., Haertzen, C. A., Hickey, I. E., et al Nitrite inhalants: Patterns of abuse in Baltimore and Washington, D.C. American Journal of Drug and Alcohol Abuse 14: 29–39, 1988.PubMedCrossRefGoogle Scholar
  62. 62.
    Mirvish, S. S., und Haverkos, H. W. Butyl nitrite in the induction of Kaposi’s sarcoma in AIDS. New England Journal of Medicine 317: 1603, 1987.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Marc A. Schuckit
    • 1
  1. 1.San Diego School of Medicine, Veterans Administration HospitalUniversity of CaliforniaSan DiegoUSA

Personalised recommendations